• Explore /
  • Poster
  • / KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).

KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).

Abstract Poster

Authors

Ashish Kamat

Ashish M. Kamat

The University of Texas MD Anderson Cancer Center, Houston, TX

Ashish M. Kamat , Joaquim Bellmunt , Toni K. Choueiri , Kijoeng Nam , Maria De Santis , Robert Dreicer , Noah M. Hahn , Rodolfo F. Perini , Arlene O. Siefker-Radtke , Guru Sonpavde , Ronald De Wit , Alfred Witjes , Stephen Michael Keefe , Dean F. Bajorin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02625961

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS4576)

DOI

10.1200/JCO.2016.34.15_suppl.TPS4576

Abstract #

TPS4576

Poster Bd #

197a

Abstract Disclosures

Similar Posters

First Author: Ashish M. Kamat

First Author: Zongren Wang

First Author: Girish S. Kulkarni

First Author: Roger Li